{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:50:28Z","timestamp":1787827828956,"version":"build-2784847793"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,5,24]],"date-time":"2015-05-24T00:00:00Z","timestamp":1432425600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,5,24]],"date-time":"2015-05-24T00:00:00Z","timestamp":1432425600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Biochem Biophys"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s12013-015-0580-1","type":"journal-article","created":{"date-parts":[[2015,5,23]],"date-time":"2015-05-23T07:37:31Z","timestamp":1432366651000},"page":"603-607","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Tirofiban Combined with Fondaparinux for Post-PCI Treatment of Patients with Acute Coronary Syndrome and Mild Renal Insufficiency"],"prefix":"10.1007","volume":"73","author":[{"given":"Hong","family":"Changjiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu","family":"Jian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Puqing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gu","family":"Xiaolong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,24]]},"reference":[{"key":"580_CR1","first-page":"2371","volume":"143","author":"P Karpati","year":"2002","unstructured":"Karpati, P. (2002). Differential diagnosis of acute coronary syndromes. Orvosi Hetilap, \n                           143, 2371\u20132376. in Hungarian.","journal-title":"Orvosi Hetilap"},{"key":"580_CR2","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1161\/CIRCRESAHA.114.302721","volume":"114","author":"JF Bentzon","year":"2014","unstructured":"Bentzon, J. F., Otsuka, F., Virmani, R., & Falk, E. (2014). Mechanisms of plaque formation and rupture. Circulation Research, \n                           114, 1852\u20131866.","journal-title":"Circulation Research"},{"key":"580_CR3","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1055\/s-0034-1370088","volume":"139","author":"F Hennersdorf","year":"2014","unstructured":"Hennersdorf, F., & Muller-Ehmsen, J. (2014). Acute coronary syndrome: Intensive care management. Deutsche Medizinische Wochenschrift, \n                           139, 1220\u20131223. in German.","journal-title":"Deutsche Medizinische Wochenschrift"},{"issue":"1","key":"580_CR4","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nrcardio.2014.156","volume":"12","author":"F Franchi","year":"2015","unstructured":"Franchi, F., & Angiolillo, D. J. (2015). Novel antiplatelet agents in acute coronary syndrome. Nature Reviews Cardiology, \n                           12(1), 30\u201347.","journal-title":"Nature Reviews Cardiology"},{"key":"580_CR5","first-page":"136","volume":"9","author":"P Gasior","year":"2013","unstructured":"Gasior, P., Desperak, P., Gierlaszynska, K., et al. (2013). Percutaneous coronary intervention in treatment of multivessel coronary artery disease in patients with non-ST-segment elevation acute coronary syndrome. Postepy W Kardiologii Interwencyjnej, \n                           9, 136\u2013145.","journal-title":"Postepy W Kardiologii Interwencyjnej"},{"key":"580_CR6","first-page":"1","volume":"15","author":"BM Lo","year":"2013","unstructured":"Lo, B. M. (2013). An evidence-based approach to acute aortic syndromes. Emergency Medicine Practice, \n                           15, 1\u201323. (quiz 23\u201324).","journal-title":"Emergency Medicine Practice"},{"key":"580_CR7","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1097\/CCM.0000000000000404","volume":"42","author":"M Legrand","year":"2014","unstructured":"Legrand, M., Mebazaa, A., Ronco, C., & Januzzi, J. L, Jr. (2014). When cardiac failure, kidney dysfunction, and kidney injury intersect in acute conditions: The case of cardiorenal syndrome. Critical Care Medicine, \n                           42, 2109\u20132117.","journal-title":"Critical Care Medicine"},{"key":"580_CR8","doi-asserted-by":"publisher","first-page":"231","DOI":"10.5603\/KP.a2013.0282","volume":"72","author":"L Koltowski","year":"2014","unstructured":"Koltowski, L., Lewandowski, A., Chojnacka, K., et al. (2014). The impact of renal insufficiency on in-hospital outcome in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary interventions. Kardiologia Polska, \n                           72, 231\u2013238.","journal-title":"Kardiologia Polska"},{"key":"580_CR9","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1159\/000127446","volume":"111","author":"T Pinkau","year":"2008","unstructured":"Pinkau, T., Ndrepepa, G., Kastrati, A., et al. (2008). Glycoprotein IIb\/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function. Cardiology, \n                           111, 247\u2013253.","journal-title":"Cardiology"},{"key":"580_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1136\/heartjnl-2011-300024","volume":"98","author":"NG Campbell","year":"2012","unstructured":"Campbell, N. G., Varagunam, M., Sawhney, V., et al. (2012). Mild chronic kidney disease is an independent predictor of long-term mortality after emergency angiography and primary percutaneous intervention in patients with ST-elevation myocardial infarction. Heart, \n                           98, 42\u201347.","journal-title":"Heart"},{"key":"580_CR11","first-page":"R1229","volume":"301","author":"F Palm","year":"2011","unstructured":"Palm, F., & Nordquist, L. (2011). Renal oxidative stress, oxygenation, and hypertension. American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, \n                           301, R1229\u2013R1241.","journal-title":"American Journal of Physiology: Regulatory, Integrative and Comparative Physiology"},{"key":"580_CR12","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0735-1097(02)02608-6","volume":"40","author":"BJ Freda","year":"2002","unstructured":"Freda, B. J., Tang, W. H., Van Lente, F., Peacock, W. F., & Francis, G. S. (2002). Cardiac troponins in renal insufficiency: Review and clinical implications. Journal of the American College of Cardiology, \n                           40, 2065\u20132071.","journal-title":"Journal of the American College of Cardiology"},{"key":"580_CR13","doi-asserted-by":"publisher","first-page":"973","DOI":"10.2147\/DDDT.S38042","volume":"7","author":"M Di Nisio","year":"2013","unstructured":"Di Nisio, M., & Porreca, E. (2013). Prevention of venous thromboembolism in hospitalized acutely ill medical patients: Focus on the clinical utility of (low-dose) fondaparinux. Drug Design, Development and Therapy, \n                           7, 973\u2013980.","journal-title":"Drug Design, Development and Therapy"},{"key":"580_CR14","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s10557-013-6444-2","volume":"27","author":"P Clemmensen","year":"2013","unstructured":"Clemmensen, P., Dridi, N. P., & Holmvang, L. (2013). Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology. Cardiovascular Drugs and Therapy, \n                           27, 239\u2013245.","journal-title":"Cardiovascular Drugs and Therapy"},{"key":"580_CR15","doi-asserted-by":"publisher","first-page":"381","DOI":"10.4330\/wjc.v6.i6.381","volume":"6","author":"S Vecchio","year":"2014","unstructured":"Vecchio, S., Varani, E., Chechi, T., et al. (2014). Coronary thrombus in patients undergoing primary PCI for STEMI: Prognostic significance and management. World Journal of Cardiology, \n                           6, 381\u2013392.","journal-title":"World Journal of Cardiology"},{"key":"580_CR16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2174\/1389200033489532","volume":"4","author":"V Pichette","year":"2003","unstructured":"Pichette, V., & Leblond, F. A. (2003). Drug metabolism in chronic renal failure. Current Drug Metabolism, \n                           4, 91\u2013103.","journal-title":"Current Drug Metabolism"},{"issue":"2","key":"580_CR17","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/ncpcardio0311","volume":"2005","author":"MT Rothman","year":"2005","unstructured":"Rothman, M. T. (2005). Drug insight: Bleeding after percutaneous coronary intervention-risks, measures and impact of anticoagulant treatment options. Nature Clinical Practice Cardiovascular Medicine, \n                           2005(2), 465\u2013474.","journal-title":"Nature Clinical Practice Cardiovascular Medicine"},{"key":"580_CR18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1179\/135100009X12525712409490","volume":"14","author":"S Hua","year":"2009","unstructured":"Hua, S., Song, C., Geczy, C. L., Freedman, S. B., & Witting, P. K. (2009). A role for acute-phase serum amyloid A and high-density lipoprotein in oxidative stress, endothelial dysfunction and atherosclerosis. Redox Report, \n                           14, 187\u2013196.","journal-title":"Redox Report"},{"key":"580_CR19","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2147\/VHRM.S6099","volume":"6","author":"F Schiele","year":"2010","unstructured":"Schiele, F. (2010). Fondaparinux and acute coronary syndromes: update on the OASIS 5\u20136 studies. Vascular Health and Risk Management, \n                           6, 179\u2013187.","journal-title":"Vascular Health and Risk Management"},{"key":"580_CR20","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.ahj.2010.08.038","volume":"160","author":"TE van Rees Vellinga","year":"2010","unstructured":"van Rees Vellinga, T. E., Peters, R. J., Yusuf, S., Afzal, R., Chrolavicius, S., O\u2019Donnell, M., et al. (2010). Efficacy and safety of fondaparinux in patients with ST-segment elevation myocardial infarction across the age spectrum. Results from the Organization for the Assessment of Strategies for Ischemic Syndromes 6 (OASIS-6) trial. American Heart Journal, \n                           160, 1049\u20131055.","journal-title":"American Heart Journal"},{"key":"580_CR21","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2174\/187152511797037475","volume":"9","author":"JF Diaz","year":"2011","unstructured":"Diaz, J. F., Cardenal, R., Gomez-Manchero, A., & Sanchez-Gonzalez, C. (2011). Safety and efficacy of tirofiban as adjunctive therapy for patients with ST-elevation myocardial infarction: A comparison versus placebo and abciximab. Cardiovascular and Hematological Agents in Medicinal Chemistry, \n                           9, 147\u2013153.","journal-title":"Cardiovascular and Hematological Agents in Medicinal Chemistry"},{"issue":"56","key":"580_CR22","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.2165\/00003495-199856060-00017","volume":"1998","author":"KJ McClellan","year":"1998","unstructured":"McClellan, K. J., & Goa, K. L. (1998). Tirofiban. A review of its use in acute coronary syndromes. Drugs, \n                           1998(56), 1067\u20131080.","journal-title":"Drugs"},{"key":"580_CR23","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1600-0536.2011.01932.x","volume":"65","author":"T Weberschock","year":"2011","unstructured":"Weberschock, T., Meister, A. C., Bohrt, K., Schmitt, J., Boehncke, W. H., & Ludwig, R. J. (2011). The risk for cross-reactions after a cutaneous delayed-type hypersensitivity reaction to heparin preparations is independent of their molecular weight: A systematic review. Contact Dermatitis, \n                           65, 187\u2013194.","journal-title":"Contact Dermatitis"}],"container-title":["Cell Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12013-015-0580-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12013-015-0580-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12013-015-0580-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12013-015-0580-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T18:11:58Z","timestamp":1602267118000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12013-015-0580-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,24]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["580"],"URL":"https:\/\/doi.org\/10.1007\/s12013-015-0580-1","relation":{},"ISSN":["1085-9195","1559-0283"],"issn-type":[{"value":"1085-9195","type":"print"},{"value":"1559-0283","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,24]]},"assertion":[{"value":"24 May 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}